Skip to main content
AIM Vaccine Co., Ltd. logo

AIM Vaccine Co., Ltd. — Investor Relations & Filings

Ticker · 6660 HKEX Manufacturing
Open in API
Filings indexed 224 across all filing types
Latest filing 2025-02-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6660

About AIM Vaccine Co., Ltd.

https://www.aimbio.com

AIM Vaccine Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines for human use. The company's mission is to produce high-quality vaccines to safeguard global health. It holds a leading position among privately-owned vaccine enterprises in its primary market. The core product portfolio includes established vaccines such as Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Inactivated Hepatitis A Vaccine (Human Diploid Cell), and Meningococcal Polysaccharide Vaccine. AIM Vaccine is also a major global supplier of rabies vaccines, committed to leading technological advancements in this area. The company actively expands its pipeline, which features advanced candidates like the 13-valent pneumonia conjugate vaccine and iterative serum-free rabies vaccine, alongside strategic investments in mRNA technology, including an mRNA COVID-19 vaccine candidate.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - HUMORAL AND CELLULAR IMMUNITY OF THE MRNA RSV VACCINE WERE SIGNIFICANTLY HIGHER THAN THOSE OF INTERNATIONALLY MARKETED PRODUCTS APPLICATION FOR CLINICAL TRIAL IN THE U.S.
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by the company on a business development (the submission of a clinical trial application for an mRNA RSV vaccine). It does not present financial results, management changes, dividends, legal actions, or an investor presentation. It is an informative regulatory announcement without fitting specific categories such as earnings release, M&A, or share issues. Thus it falls into the fallback category of general regulatory filings.
2025-02-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
Regulatory Filings Classification · 1% confidence The document is a routine monthly return (Form FF301) submitted to the Hong Kong Stock Exchange detailing movements in authorized share capital, issued shares, share options, etc., under Chapter 19B of the Listing Rules. It is neither an annual/interim report nor a dividend notice or management change announcement but rather a statutory compliance filing. It fits the fallback category of a general regulatory announcement. Therefore, it is classified as a Regulatory Filing (RNS).
2025-01-06 English
VOLUNTARY ANNOUNCEMENT - SECOND GENERATION OF HIGHLY-EFFECTIVE ABSORBED TETANUS VACCINE OBTAINED THE CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by AIM Vaccine Co., Ltd. regarding obtaining clinical trial approval for a new vaccine. It does not present financial results, management changes, dividend notices, or capital transactions. It is an operational update filed with the Hong Kong Exchange as a regulatory announcement. It does not constitute a full report, presentation, or specific transaction category. Therefore, it falls under the general Regulatory Filings category (RNS).
2024-12-19 English
VOLUNTARY ANNOUNCEMENT - SUSPENSION CULTURE INFLUENZA VACCINE (MDCK CELLS) WITH NEW TECHNOLOGICAL ROUTE OBTAINED THE CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement by AIM Vaccine Co., Ltd. regarding the clinical trial approval of a new influenza vaccine. It does not present financial results, changes in management, or formal regulatory filings like an annual or interim report. It does not attach or publish a substantive report, but provides a business update. This falls under general regulatory/announcement filings that do not fit more specific categories, so it should be classified as a Regulatory Filing (RNS).
2024-12-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Regulatory Filings Classification · 1% confidence The document is a mandatory monthly return submitted to the Hong Kong Exchange detailing movements in authorized share capital, issued shares, treasury shares, and share options under Chapter 19B of the Listing Rules. It is not announcing an event like a dividend or takeover, nor is it an earnings release, annual or interim report. It is a routine regulatory submission falling under general regulatory filings. Therefore, it is classified as RNS (Regulatory Filings).
2024-12-02 English
CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG
Regulatory Filings
2024-11-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.